#United States #South San Francisco #Aranscia #InterVenn Biosciences #GlycoKnow

InterVenn Biosciences and Aranscia: A Partnership for Advanced Ovarian Cancer Diagnosis

In an exciting development in the field of medical diagnostics, InterVenn Biosciences has announced a strategic partnership with Aranscia to advance the commercialization of its innovative GlycoKnow™ test for ovarian cancer. This collaboration aims to reshape diagnostic workflows and improve patient outcomes in the realm of women's health and oncology.

Who Are the Partners?

InterVenn Biosciences, based in South San Francisco, is a leader in precision diagnostics that leverages glycoproteomics to enhance liquid biopsy processes. The company's GlycoKnow™ test aspires to improve early detection of ovarian cancer, ultimately saving lives through timely intervention.

On the other hand, Aranscia is a globally recognized company specializing in diagnostic solutions and clinical workflows. With a strong reputation for creating innovative technologies, Aranscia supports healthcare providers with their comprehensive suite of tools aimed at improving patient care outcomes.

The GlycoKnow™ Test

The GlycoKnow™ test is a groundbreaking blood test that distinguishes between malignant ovarian tumors and benign pelvic masses. This distinction is critical, given that approximately 80% of pelvic masses are non-cancerous. By simplifying the diagnostic process, GlycoKnow™ can assist clinicians in delivering appropriate care swiftly, avoiding unnecessary surgeries, and minimizing complications.

Enhancing Diagnostic Workflows

This partnership will harness Aranscia's extensive technological expertise and clinical resources to enhance InterVenn's testing and diagnostic services. Leveraging Aranscia's software solutions, including Spesana and 2bPrecise, InterVenn aims to facilitate efficient clinical workflows. These tools are designed to be compatible with existing electronic medical records (EMR), thereby streamlining the diagnostic process across various health settings.

Andrew Quong, CEO of InterVenn, expressed enthusiasm for the partnership, stating, “We are pleased to join forces with the Aranscia team. Their proven experience in enabling personalized diagnostic programs is invaluable to our mission. Together, we aim to improve cancer care through our glycoproteomic innovations.”

In their collaboration, both companies will also focus on logistical program support through AccessDx Laboratory, another subsidiary of Aranscia, to ensure that the GlycoKnow™ test reaches wider communities and healthcare institutions.

The Bigger Picture

This collaboration goes beyond just developing a diagnostic test; it aims to change the landscape of ovarian cancer care. By providing advanced tools to clinicians, InterVenn and Aranscia are paving the way for precision healthcare that is accessible to all women, particularly those at risk of ovarian cancer.

Bryon Cipriani, CEO of Aranscia, noted, “We are proud to support InterVenn’s mission in improving detection efficiencies and care against ovarian cancer through our partnership. This initiative underscores our commitment to democratizing the access to precision medical care.”

Future Prospects

The success of the GlycoKnow™ test could lead to further research and the potential development of additional tests in the future. This partnership is not just about one product; it symbolizes a significant step forward in cancer diagnostics and personalized medicine.

InterVenn's pioneering use of AI and machine learning within its GlycoVision™ platform continues to position it as a key player in the diagnostics landscape. With a focus on the human glycoproteome, the company aims to provide nuanced insights into disease detection and management.

As the partnership unfolds, both InterVenn and Aranscia are set to impact how oncology and women’s health are approached, potentially altering countless lives for the better.

For further information about the GlycoKnow™ test or to learn about participating in InterVenn’s early access program, visit InterVenn’s official website.